Insmed Incorporated
INSM
Rankning i aktier
#1108
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aktiekurs
$95.65
Senast synkroniserad: 2026-10-19
Marknadsvärde
$20.89B
Förändring (1 dag)
-0.65%
Förändring (1 år)
-43.04%
Land
US
Handel Insmed Incorporated (INSM)
Kategori
Healthcare
EPS för Insmed Incorporated (INSM)
EPS per June 2026 TTM: $-4.11
Enligt Insmed Incorporateds senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-4.11. Vid slutet av 2023 hade bolaget ett EPS på $-5.34, en ökning jämfört med EPS från 2022 som var $-3.91.
EPS-historik för Insmed Incorporated från 2000 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-4.11 | -26.21% |
| 2024 | $-5.57 | 4.31% |
| 2023 | $-5.34 | 36.57% |
| 2022 | $-3.91 | 0.77% |
| 2021 | $-3.88 | 28.90% |
| 2020 | $-3.01 | 0.00% |
| 2019 | $-3.01 | -28.67% |
| 2018 | $-4.22 | 46.02% |
| 2017 | $-2.89 | 1.40% |
| 2016 | $-2.85 | 41.09% |
| 2015 | $-2.02 | 9.78% |
| 2014 | $-1.84 | 15.00% |
| 2013 | $-1.60 | 2.56% |
| 2012 | $-1.56 | -39.06% |
| 2011 | $-2.56 | 422.45% |
| 2010 | $-0.49 | -105.27% |
| 2009 | $9.30 | -826.56% |
| 2008 | $-1.28 | -26.44% |
| 2007 | $-1.74 | -70.46% |
| 2006 | $-5.89 | -29.88% |
| 2005 | $-8.40 | 20.86% |
| 2004 | $-6.95 | 140.48% |
| 2003 | $-2.89 | -73.75% |
| 2002 | $-11.01 | -2.65% |
| 2001 | $-11.31 | -74.06% |
| 2000 | $-43.60 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -521.41% |
US
|
|
| $-7.98 | 94.16% |
US
|
|
| $-5.29 | 28.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -774.94% |
NL
|
